“Micronization is a well-established technology to help improve the solubility of oral drugs and there continues to be a growing need for safe manufacturing and containment technologies required for the development of highly potent APIs,” said James Walter, vice president operations, oral and specialty delivery. “These expansions provide the increased capacity needed to meet current and future demand for high potent, high value micronization.”

As well as micronization, the New Jersey, US-headquartered company said the two sites offer expertise in other particle size engineering technologies such as jet milling, mechanical milling, cryogenic milling and associated analytical services.

Earlier this month, Catalent launched its Xpress Pharmaceuticals service to accelerate the development of oral drugs through Phase 1 clinical studies. The CDMO said that by integrating formulation development, on-demand clinical manufacturing, regulatory support and clinical testing, the service can reduce both the cost and time needed to complete first-in-human trials.

Author: Elaine Burridge, Freelance Journalist